Combining biological therapies in patients with inflammatory bowel disease : a Finnish multi-centre study

Show full item record



Permalink

http://hdl.handle.net/10138/346623

Citation

Eronen , H , Kolehmainen , S , Koffert , J , Koskinen , I , Oksanen , P , Jussila , A , Huhtala , H , Sipponen , T & Ilus , T 2022 , ' Combining biological therapies in patients with inflammatory bowel disease : a Finnish multi-centre study ' , Scandinavian Journal of Gastroenterology , vol. 57 , no. 8 , pp. 936-941 . https://doi.org/10.1080/00365521.2022.2045350

Title: Combining biological therapies in patients with inflammatory bowel disease : a Finnish multi-centre study
Author: Eronen, Heli; Kolehmainen, Sara; Koffert, Jukka; Koskinen, Inka; Oksanen, Pia; Jussila, Airi; Huhtala, Heini; Sipponen, Taina; Ilus, Tuire
Contributor organization: Faculty of Medicine
University of Helsinki
Clinicum
Gastroenterologian yksikkö
HUS Abdominal Center
Date: 2022-08-03
Language: eng
Number of pages: 6
Belongs to series: Scandinavian Journal of Gastroenterology
ISSN: 0036-5521
DOI: https://doi.org/10.1080/00365521.2022.2045350
URI: http://hdl.handle.net/10138/346623
Abstract: Background and aims Therapy with two concomitant biologicals targeting different inflammatory pathways has emerged as a new therapy option for treatment refractory inflammatory bowel disease (IBD). Data on the efficacy and safety of dual biological therapy (DBT) are scarce and are investigated in this study. Materials and methods Data on all patients treated with a combination of two biologicals in four Finnish tertiary centres were collected and analysed. Remission was assessed by a physician on the basis of biomarkers, endoscopic evaluation and alleviation of symptoms. Results A total of 16 patients with 22 trials of DBT were included. Fifteen patients had Crohn's disease. The most common combination of DBT was adalimumab (ADA) and ustekinumab (USTE; 36%) with median follow-up of nine months (range 2-31). Altogether seven (32%) patients were in remission at the end of follow-up and in two trials response to DBT was assessed to be partial with the relief of patient symptoms. In a total of four trials DBT reduced the need for corticosteroids. The majority of patients achieving a response to DBT were treated with the combination of ADA and USTE (56%). At the end of follow-up all nine (41%) patients responding to DBT continued treatment. Infection complications occurred in three patients (19%). Conclusion DBT is a promising alternative treatment for refractory IBD, and half of our patients benefitted from it. More data on the efficacy and safety of DBT are needed especially in long-term follow up.
Subject: Inflammatory bowel disease
dual biological therapy
combining biological therapies
adalimumab
golimumab
vedolizumab
ustekinumab
EVIDENCE-BASED CONSENSUS
CROHNS-DISEASE
ULCERATIVE-COLITIS
CLINICAL-COURSE
VEDOLIZUMAB
MANAGEMENT
DIAGNOSIS
SAFETY
3121 General medicine, internal medicine and other clinical medicine
Peer reviewed: Yes
Rights: cc_by_nc_nd
Usage restriction: openAccess
Self-archived version: publishedVersion


Files in this item

Total number of downloads: Loading...

Files Size Format View
Combining_biolo ... ish_multi_centre_study.pdf 1.244Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record